Uipath Stock News

UiPath (NASDAQ:PATH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “UiPath Inc. offers an end-to-end platform for automation, combining Robotic Process Automation solution for digital business operations. UiPath Inc. is based in New York, United States. “ PATH […]

ARK Genomic ETF: Likely Economic Victim With Low Institutional Interest

Related Stocks: PATH , TEAM , UBER , SPGI , CFLT , YMM , IT , PTON , BEKE , EFX , SQ , NTES , SAP , AVB , WELL , EQR , CCL , BAM , PINS , MU , CMLF , BZ , OLO , SANA ,

One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a huge purchase on Friday.

UiPath (NASDAQ:PATH) had its price target reduced by Wells Fargo & Company from $65.00 to $50.00 in a report released on Thursday morning, The Fly reports. They currently have an equal weight rating on the healthcare companys stock. The analyst notes UiPath delivered another solid beat across top-line metrics for Q3, including a quarterly record []

Berenberg Bank upgraded shares of UiPath (NASDAQ:PATH) from a hold rating to a buy rating in a report published on Thursday morning, PriceTargets.com reports. Berenberg Bank currently has $64.00 price objective on the healthcare companys stock. Several other research analysts have also recently issued reports on the stock. Canaccord Genuity upgraded shares of UiPath to []

Shares of UiPath Inc. (NASDAQ:PATH) have been given an average recommendation of Hold by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating on the company. The average []

UiPath (NASDAQ:PATH)s stock had its neutral rating restated by equities researchers at Macquarie in a report issued on Thursday, The Fly reports. They currently have a $55.00 price target on the healthcare companys stock, down from their previous price target of $71.00. Macquaries price target would suggest a potential upside of 24.86% from the stocks []

UiPath (NASDAQ:PATH) had its price objective dropped by KeyCorp from $86.00 to $69.00 in a research report issued to clients and investors on Thursday, The Fly reports. The firm presently has an overweight rating on the healthcare companys stock. KeyCorps target price indicates a potential upside of 56.64% from the companys previous close. The analysts []

Related Stocks: SPOT , PATH , APT , DASH , RBLX , GNRC , SQ , TTD , S , S , CDAY , 03690 , FIS , VRTX , CMI , EFX , MQ , PLTK ,

UiPath (NASDAQ:PATH) was upgraded by Berenberg Bank from a hold rating to a buy rating in a report released on Thursday, PriceTargets.com reports. The brokerage currently has a $64.00 price target on the healthcare companys stock. Berenberg Banks price target suggests a potential upside of 45.29% from the companys previous close. A number of other [] The post UiPath (NASDAQ:PATH) Rating Increased to Buy at Berenberg Bank appeared first on ETF Daily News .

UiPath (NASDAQ:PATH) had its target price lowered by research analysts at Truist from $82.00 to $75.00 in a report issued on Thursday, The Fly reports. The firm presently has a buy rating on the healthcare companys stock. Truists price target points to a potential upside of 70.26% from the companys previous close. The analyst says []

UiPath (NASDAQ:PATH) had its target price dropped by analysts at Truist from $82.00 to $75.00 in a research note issued on Thursday, The Fly reports. The firm currently has a buy rating on the healthcare companys stock. Truists price objective would indicate a potential upside of 70.26% from the companys current price. The analyst says []

The digital transformation of the global economy is a major tailwind for these robotics stocks.